Pancreatic Cancer: A Caregiver's Perspective

CM24 plus Opdivo and chemo improved survival in pancreatic cancer with CEACAM1 biomarkers, supporting a biomarker-driven phase 2b study.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

U.S. medical centers are seeking FDA authorization for the compassionate use — or expanded access — of Namodenoson for patients with pancreatic cancer.

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

A test to identify higher risk of developing urinary side effects after radiation in patients with prostate cancer was confirmed by data from a new study.

Dr. Sheri Yolanda Prentiss discusses lymphedema as a result of cancer treatment and shares resources that exist for patients coping with this condition.